LINDSAY GREGG: Open Payments
NPI 1700563913 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,758 in 120 payments from 20 companies in 2025. Trend: 2023 $227 · 2024 $1,218 · 2025 $1,758
Food & beverage: $1,698Education: $61
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 22 | $334 |
| Supernus Pharmaceuticals, Inc. | 22 | $213 |
| Neurocrine BioSciences, Inc. | 15 | $205 |
| Otsuka America Pharmaceutical, Inc. | 12 | $178 |
| ABBVIE INC. | 11 | $175 |
| Alkermes, Inc. | 10 | $156 |
| Teva Pharmaceuticals USA, Inc. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Lundbeck LLC | 3 | $58 |
Products named: FANAPT, Qelbree, INGREZZA, REXULTI, VRAYLAR, ARISTADA, AUSTEDO XR, CAPLYTA.
Industry payments across IN — which companies pay providers there.
